Benserazide·HCl (Ro 4-4602) is a small molecule inhibitor of extracerebral DDC (aromatic L-aminoacid decarboxylase), also known as DOPA decarboxylase. This protein is responsible for decarboxylating L-DOPA to dopamine, 5-hydroxytryptophan to serotonin, and tryptophan to tryptamine. L-DOPA is delivered directly to subjects suffering from a dopaminergic dysfunction such as in Parkinson's disease and dopamine-responsive dystonia - L-DOPA is the natural precursor to dopamine and freely passes the blood brain barrier, while dopamine itself does not. Inhibition of the extracerebral decarboxylation of L-DOPA into dopamine by Benserazide increases the availability of L-DOPA for movement into the brain and subsequent conversion to dopamine. Benserazide·HCl (Ro 4-4602) is an inhibitor of TH and TPH.
1. Pinder, R.M., et al. 1976. Drugs. 11: 329-377. PMID: 782834
2. Marion, M.H., et al. 1987. Adv Neurol. 45: 493-496. PMID: 3548262
3. Merims, D., et al. 2008. Parkinsonism Relat. Disord. 14: 273-280. PMID: 17988927
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.